Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Diez años del "Programa de evaluación de desempeño de laboratorios de inmunogenética" y su impacto en la "Red de donación y trasplantes"].
Biomedica
December 2024
Grupo Red de Donación y Trasplantes, Instituto Nacional de Salud, Bogotá, D. C., Colombia.
Introducción. El uso de las pruebas inmunológicas antes del trasplante de órganos sólidos es fundamental para disminuir el riesgo de rechazo y las complicaciones de los trasplantes. Los sistemas de control de calidad de los laboratorios que las realizan son, por tanto, necesarios para la práctica clínica.
View Article and Find Full Text PDFImmunopeptidomics for autoimmunity: unlocking the chamber of immune secrets.
NPJ Syst Biol Appl
January 2025
Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
T cells mediate pathogenesis of several autoimmune disorders by recognizing self-epitopes presented on Major Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) complex. The majority of autoantigens presented to T cells in various autoimmune disorders are not known, which has impeded autoantigen identification. Recent advances in immunopeptidomics have started to unravel the repertoire of antigenic epitopes presented on MHC.
View Article and Find Full Text PDFFactors affecting the efficacy of human leukocyte antigen-selected platelet provision: A large retrospective study in the United Kingdom.
Transfus Med
January 2025
Histocompatibility & Immunogenetics, NHSBT Colindale Centre, London, UK.
Background: A large, retrospective study was designed to interrogate current NHS Blood and Transplant (NHSBT) HLA matching strategies for the provision of HLA selected platelets (HLA SP) and to determine whether additional factors such as ABO blood group matching, patient diagnosis, patient and/or donor age, sex, ethnicity, age of platelet unit at transfusion and possibly seasonal variation also play a role in transfusion efficacy.
Materials And Methods: Data for 56 640 HLA SP transfusions over a 3-year period were collected. Transfusions with missing data for any factor under consideration were excluded, resulting in a cohort of 13 044 transfusions for analysis.
The Clinical Significance of HLA Compatibility Scores in Lung Transplantation.
Transpl Int
January 2025
Department of Chronic Diseases, Metabolism and Ageing, Laboratory for Respiratory Diseases and Thoracic Surgery, Faculty of Medicine, KU Leuven, Leuven, Belgium.
Lung transplantation is a life-saving therapeutic option for many chronic end-stage pulmonary diseases, but long-term survival may be limited by rejection of the transplanted organ. Since HLA disparity between donor and recipient plays a major role in rejection, we performed a single center, retrospective observational cohort analysis in our lung transplant cohort (n = 128) in which we calculated HLA compatibility scores for B-cell epitopes (HLAMatchmaker, HLA-EMMA), T-cell epitopes (PIRCHE-II) and missing self-induced NK cell activation (KIR Ligand Calculator). Adjusted Cox proportional hazards model was used to investigate the association between mismatched scores and time to development of donor-specific antibodies (DSA) post-transplant, time to first biopsy-proven acute rejection episode, freedom from CLAD, graft survival and overall survival.
View Article and Find Full Text PDFEvolution of anti-MICA antibodies after imlifidase infusion for a high immunological risk kidney transplantation.
Hum Immunol
January 2025
Service de Néphrologie, Dialyse et Transplantation, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Laboratoire d'ImmunoRhumatologie Moléculaire, Institut national de la santé et de la recherche médicale (INSERM) UMR_S1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France; Laboratoire d'Excellence (LabEx) TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France; Institut Thématique Interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Strasbourg, France. Electronic address:
Imlifidase is an endopeptidase known for cleaving anti-Human Leucocyte Antigen donor-specific antibodies (DSA) to allow high-risk kidney transplantation. However, it lacks comprehensive data regarding its effect on alloantibodies targeting other histocompatibility antigens, such as Major Histocompatibility Complex class I chain-related protein A (MICA). This study describes the dynamics of anti-MICA antibodies following imlifidase administration in a kidney transplant recipient with anti-MICA*002 preformed DSA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!